Posts tagged central nervous system
WB starts Biohaven at OP

William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26.

Read More
BTIG starts Axsome at buy

BTIG launched coverage of Axsome Therapeutics (NASDAQ:AXSM) with a “buy” rating and $14 price target. The stock closed at $3.80 on May 18.

Read More
IntelGenx, Chemo Group expand partnership

IntelGenx (OTCQX:IGXT; TSX-V:IGX) strengthened its relationship with Chemo Group by signing a term sheet for co-development and commercialization of a generic tablet for the central nervous system (CNS) on a worldwide basis.

Read More
Tonix Pharma AFFIRM trial fails

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) said its Phase 3 AFFIRM study, designed to evaluate the safety and efficacy of TNX-102 SL in patients with fibromyalgia, did not achieve statistical significance in the primary efficacy endpoint.

Fibromyalgia is a multi-symptom disorder that originates in the central nervous system and is characterized by widespread pain, non-restorative sleep, fatigue, and disability.

Read More
Stifel starts Voyager Therapeutics at buy

Stifel Research launched coverage of Voyager Therapeutics (NASDAQ:VYGR) with a “buy” rating and 12-month price target of $33. The stock closed at $11.81 on Thursday.

Voyager is a clinical stage-gene therapy company with the potential to be the market leader in design, development and commercialization of gene products focused on diseases of the central nervous system (CNS), writes analyst Katherine Breedis.

Read More
ARIAD reports updated data in pivotal ALTA study

ARIAD Pharmaceuticals (NASDAQ:ARIA) has reported updated clinical data for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had experienced disease progression on crizotinib therapy.

The data show that, of patients on the 180 mg regimen (Arm B) with a median follow-up of 8.3 months, 54% achieved a confirmed objective response, the trial’s primary endpoint. In this arm, the median progression free survival exceeded one year (12.9 months) in this post-crizotinib setting.

Read More